MRC2 and tuberculosis: More conventionally available reagents, such as C reactive protein (CRP), IL-6, IP-10, and TNF-α exhibit a promising position for the TB treatment monitoring (19), while TSP4 (thrombospondin 4), TIMP-2 (tissue inhibitor of metalloproteinase-2), SEPR (fibroblast activation protein α), MRC-2 (mannose receptor C type 2), antithrombin III, serum amyloid A, CRP, phospholipase A2, hepcidin, and LPS-binding protein exhibit significant expression differences during the intensive phase of TB therapy (20).